Betaxolol in Patients with Glaucoma and Asthma

Buskirk, E. Michael Van; Weinreb, Robert N.; Berry, David P.; Lustgarten, Jacqueline S.; Podos, Steven M.; Drake, Margaret

doi:10.1016/0002-9394(86)90941-4

Cited by 59 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar study, timolol produced a 25% reduction in FEV1. 67 Van Buskirk et al 68 reported that 11 patients with glaucoma and asthma were able to receive betaxolol with no exacerbation of their pulmonary symptoms and without deterioration in pulmonary function tests. Furthermore, Diggory et al 69 showed an increase of 13% and 8% in peak flow rate and FEV1, respectively, in patients with no history of airway disease when their prescription was changed from timolol to betaxolol.…”

Section: Betaxololmentioning

confidence: 98%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

Glaucoma and ocular hypertension are highly prevalent conditions in individuals over the age of 40 and are commonly seen together in patients with cardiovascular disease. Many of the antiglaucoma medications, when systemically absorbed, affect the sympathetic and parasympathetic nervous systems of patients and can cause cardiovascular toxicity. Such adverse effects are frequently associated with the long-term use of potentially toxic agents in elderly people, who are most prone to chronic eye disease. Moreover, patients may not associate their symptoms with the topical eye medications, and consequently may not report adverse drug effects. Drug-drug interactions can also occur when patients are taking medications for both cardiovascular disease and glaucoma. In this review, the systemic toxicity of these agents is reviewed, along with possible drug-drug interactions. Mention is made of other antiglaucoma medications used alone and in combination with topical beta-blockers. Identification of genetic loci-a bold new step toward glaucoma treatment-is mentioned briefly at the end of the article.

show abstract

Section: Betaxololmentioning

confidence: 98%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…Our study helps to interpret other reports of patients who were switched from one ocu lar hypotensive medication to another, such as one evaluating befunolol [11] and another evaluating betaxolol [12], In the befunolol study, Tanaka et al [11] switched patients from a regimen of timolol in combination with other agents to befunolol. The befunolol combination treatment reduced IOP an aver age of 2 mm Hg more than the timolol com bination treatment.…”

Section: Discussionmentioning

confidence: 75%

“…The befunolol combination treatment reduced IOP an aver age of 2 mm Hg more than the timolol com bination treatment. In the betaxolol study [12], asthmatic glaucoma patients sensitive to timolol had betaxolol added to their maximal medical therapy and experienced a further reduction in IOP of 4 mm Hg. Since neither study had a timolol control group, one may question whether the beneficial effects were produced by the newly added drugs or by increased patient compliance with the treat ment regimen, as seen in our study results.…”

Section: Discussionmentioning

confidence: 99%

Effect of Changing Medication Regimens in Glaucoma Patients

Novack¹,

David²,

Lee³

et al. 1988

Ophthalmologica

View full text Add to dashboard Cite

When glaucoma medication fails to adequately control intraocular pressure (IOP), a second medication is frequently added. Before adding a second drug to patients whose IOP was no longer controlled by 0.5% timolol, we tested the effect of switching to another beta blocker, levobunolol (0.5 or 1%). We also evaluated the effect of study participation on compliance in the control group continuing to receive 0.5% timolol. In each treatment group, the IOP of approximately 30–40% of the patients was successfully controlled for the 3-month study period. The remaining patients did not exhibit significant pressure reductions and were dropped from the study within 2 weeks. We concluded that (1) the results of’switch’ studies without a control group must be interpreted carefully, and (2) the initiation of a ‘new regimen’ with an equieffective beta blocker may be sufficient to increase compliance and thereby control IOP.

show abstract

“…The reason may be its cardioselectivity, lipophilicity and greater degree of plasma protein binding compared with timolol (Buckley et al, 1990). Experimental studies with cardioselective ocular ,-adrenoceptor blockers in healthy volunteers (Cervantes et al, 1986;LeJeunne et al, 1990) as well as clinical studies in asthmatics (Brooks et al, 1987;Cervantes et al, 1986;Dunn et al, 1986;Ofner & Smith, 1987;Schoene et al, 1984;Spiritus & Casciari, 1985;Van Buskirk et al, 1986) demonstrated a lack of measurable changes in airway calibre. On the other hand, systemic adverse effects have been occasionally reported with betaxolol (Bauer et al, 1991;Harris et al, 1986;LeJeunne et al, 1990;Nelson & Kuitsky, 1987;Weinreb et al, 1988;Zabel & MacDonald, 1987).…”

Section: Discussionmentioning

confidence: 99%

“…Especially noncardioselective ,B-adrenoceptor blockers such as timolol, metipranolol, carteolol, levobunolol, pindolol, befunolol, and others result in systemic Iadrenoceptor blockade in healthy volunteers (Bacon et al, 1989, Berlin et al, 1987Cervantes et al, 1986;LeJeunne et al, 1990;Mekki et al, 1984) as well as in patients with obstructive airway disease (Cervantes et al, 1986;Dunn etal., 1986;Hugues etal., 1987;Schoene et al, 1984;Spiritus & Casciari, 1985). Systemic ,3-adrenoceptor blocking effects have been reported to be minimal or completely absent in patients with obstructive airway disease following cardioselective ocular betaxolol (Brooks et al, 1987;Cervantes et al, 1986;Dunn et al, 1986;Ofner & Smith, 1987;Schoene etal., 1984;Spiritus & Casciari, 1985;Van Buskirk et al, 1986).…”

Section: Introductionmentioning

confidence: 99%